Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus

American Journal of Epidemiology

Volumn 171, Issue 7, 2010, Pages 817-825

  Bogaards, Johannes A ^a,b   Xiridou, Maria ^b   Coupé, Veerle M H ^a   Meijer, Chris J L M ^a   Wallinga, Jacco ^b,c   Berkhof, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bayesian statistics; Disease transmission; Human papillomavirus 16; Human papillomavirus 18; Infectious; Models; Papillomavirus infections; Prevalence; Theoretical

Indexed keywords

VIRUS DNA;

AGE STRUCTURE; BAYESIAN ANALYSIS; CANCER; DISEASE PREVALENCE; DISEASE TRANSMISSION; HEALTH RISK; IMMUNITY; INFECTIOUS DISEASE; SEXUAL BEHAVIOR; VACCINATION; VIRAL DISEASE;

ARTICLE; CONTROLLED STUDY; HEALTH SURVEY; HETEROSEXUALITY; HIGH RISK PATIENT; INFECTION RESISTANCE; NETHERLANDS; PREDICTION; PREVALENCE; SEXUAL BEHAVIOR; VACCINATION; VERRUCA VULGARIS; VIRUS TRANSMISSION; WART VIRUS;

ADULT; AGE DISTRIBUTION; AGED; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, ACTIVE; LONGITUDINAL STUDIES; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REGRESSION ANALYSIS; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; VACCINATION;

NETHERLANDS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS - 18; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 77950432041     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp466     Document Type: Article

References (40)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human pap-illomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19
2. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265 (Pubitemid 34293391)
3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527 (Pubitemid 36159887)
4. Schiffman M, Castle PE, Jeronimo J, et al. Human papilloma-virus and cervical cancer. Lancet. 2007;370(9590):890-907
5. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580):2161-2170
6. Müller M, Gissmann L. A long way: history of the prophylactic papillomavirus vaccine. Dis Markers. 2007; 23(4):331-336
7. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York, NY: Oxford University Press; 1991
8. Diekmann O, Heesterbeek JAP. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation. New York, NY: John Wiley & Sons, Inc; 2000
9. Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton, NJ: Princeton University Press; 2008
10. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine. 2007;26(1):128-139
11. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359(8):821-832
12. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom [electronic article]. BMJ. 2008;337(172):a769
13. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses [electronic article]. PLoS Med. 2006;3(5):e138
14. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000; 181(6):1911-1919
15. af Geijersstam V, Eklund C, Wang Z, et al. A survey of sero-prevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer. 1999;80(4):489-493 (Pubitemid 29047509)
16. Jit M, Vyse A, Borrow R, et al. Prevalence of human papil-lomavirus antibodies in young female subjects in England. Br J Cancer. 2007;97(7):989-991 (Pubitemid 47519301)
17. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population [electronic article]. PLoS Pathog. 2008;4(6):e1000091 (Pubitemid 351930624)
18. Carter JJ, Madeleine MM, Shera K, et al. Human papilloma-virus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001;61(5):1934-1940 (Pubitemid 32692010)
19. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13(2):324-327 (Pubitemid 38222568)
20. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(suppl 1):S97-S106
21. Garnett GP, Kim JJ, French K, et al. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24(suppl 3):S3/178-S3/186
22. Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine. 2008; 26(suppl 10):K76-K86
23. de Graaf H, Meijer S, Poelman J, et al. Sex Below the Age of 25: Sexual Health of Youth in the Netherlands in 2005 [in Dutch]. Delft, the Netherlands: Eburon Academic Publishers; 2005. (Rutgers Nisso Groep studies, no. 7)
24. Bakker F, Vanwesenbeeck I, eds. Sexual Health in the Netherlands in 2006 [in Dutch]. Delft, the Netherlands: Eburon Academic Publishers 2006. (Rutgers Nisso Groep studies, no. 9).
25. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008; 198(6):827-835
26. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110(1):94-101 (Pubitemid 38507208)
27. Bulkmans NW, Berkhof J, Bulk S, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer. 2007;96(9):1419-1424 (Pubitemid 46685773)
28. Coupé VM, Berkhof J, Bulkmans NW, et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98(3):646-651 (Pubitemid 351214513)
29. Berkhof J, Bulkmans NW, Bleeker MC, et al. Human papil-lomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1268-1273 (Pubitemid 44125280)
30. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007;97(9): 1322-1328
31. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5\+/GP6(\+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35(3):791-795
32. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516-520
33. Lenselink CH, Melchers WJ, Quint WG, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands [electronic article]. PLoS One. 2008;3(11):e3743
34. Af Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis. 1998;177(6):1710-1714
35. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev. 2005;14(1): 283-288
36. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163(6):534-542
37. Burchell AN, Tellier PP, Hanley J, et al. Human papilloma-virus infections among couples in new sexual relationships. Epidemiology. 2010;21(1):31-37
38. King AA, Ionides EL, Pascual M, et al. Inapparent infections and cholera dynamics. Nature. 2008;454(7206):877-880
39. Cauchemez S, Valleron AJ, Boëlle PY, et al. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature. 2008;452(7188):750-754
40. van der Aa MA, Pukkala E, Coebergh JW, et al. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer. 2008;122(8): 1854-1858